erlotinib hydrochloride has been researched along with Malignant Mesothelioma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; De Perrot, M; Fujino, K; Hatanaka, KC; Hatanaka, Y; Hu, HP; Jin, CS; Kaga, K; Kanno, H; Kato, T; Lee, D; Matsui, Y; Matsuno, Y; Ujiie, H; Wada, H; Weersink, RA; Wilson, BC; Wu, L; Yasufuku, K; Zheng, G | 1 |
1 other study(ies) available for erlotinib hydrochloride and Malignant Mesothelioma
| Article | Year |
|---|---|
Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Folate Receptor 1; Humans; Lipids; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice, Nude; Middle Aged; Nanoparticles; Photochemotherapy; Pleural Neoplasms; Porphyrins; Protein Kinase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |